DK1656346T3 - 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme - Google Patents

1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme

Info

Publication number
DK1656346T3
DK1656346T3 DK04734774T DK04734774T DK1656346T3 DK 1656346 T3 DK1656346 T3 DK 1656346T3 DK 04734774 T DK04734774 T DK 04734774T DK 04734774 T DK04734774 T DK 04734774T DK 1656346 T3 DK1656346 T3 DK 1656346T3
Authority
DK
Denmark
Prior art keywords
tetra
treatment
respiratory diseases
substituted indole
indole
Prior art date
Application number
DK04734774T
Other languages
Danish (da)
English (en)
Inventor
Roger Bonnert
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1656346T3 publication Critical patent/DK1656346T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04734774T 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme DK1656346T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds
PCT/SE2004/000808 WO2004106302A1 (en) 2003-05-27 2004-05-25 Novel substituted 3-sulfur indoles

Publications (1)

Publication Number Publication Date
DK1656346T3 true DK1656346T3 (da) 2009-06-15

Family

ID=33492578

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10180348.4T DK2281815T3 (da) 2003-05-27 2004-05-25 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
DK08165755.3T DK2025670T3 (da) 2003-05-27 2004-05-25 Anvendelse af 3-phenylthio-1H-indol-1-eddikesyre-derivater som modulatorer af CRTh2-receptor aktivitet
DK04734774T DK1656346T3 (da) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10180348.4T DK2281815T3 (da) 2003-05-27 2004-05-25 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
DK08165755.3T DK2025670T3 (da) 2003-05-27 2004-05-25 Anvendelse af 3-phenylthio-1H-indol-1-eddikesyre-derivater som modulatorer af CRTh2-receptor aktivitet

Country Status (31)

Country Link
US (4) US7687535B2 (is)
EP (3) EP2025670B1 (is)
JP (2) JP4541361B2 (is)
KR (3) KR101067535B1 (is)
CN (2) CN1795174B (is)
AR (1) AR044552A1 (is)
AT (3) ATE425965T1 (is)
AU (1) AU2004242624B2 (is)
BR (1) BRPI0410711B8 (is)
CA (1) CA2526866C (is)
CO (1) CO5630030A2 (is)
CY (3) CY1109104T1 (is)
DE (2) DE602004031894D1 (is)
DK (3) DK2281815T3 (is)
ES (3) ES2361485T3 (is)
HK (3) HK1090635A1 (is)
HR (3) HRP20090281T1 (is)
IL (4) IL171928A (is)
IS (2) IS2722B (is)
MX (1) MXPA05012680A (is)
MY (1) MY144483A (is)
NO (1) NO20056130L (is)
NZ (1) NZ543722A (is)
PL (3) PL2025670T3 (is)
PT (3) PT1656346E (is)
RU (1) RU2361860C2 (is)
SE (2) SE0301569D0 (is)
SI (3) SI2281815T1 (is)
TW (2) TW201024261A (is)
WO (1) WO2004106302A1 (is)
ZA (1) ZA200509598B (is)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0508540B8 (pt) 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
CA2601979C (en) 2005-04-21 2014-06-17 Laboratoires Serono S.A. 2,3 substituted pyrazine sulfonamides
CA2602965C (en) 2005-05-24 2013-12-31 Laboratoires Serono S.A. Tricyclic spiro derivatives as crth2 modulators
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
PT1928457E (pt) * 2005-09-30 2013-02-19 Pulmagen Therapeutics Asthma Ltd Quinolinas e sua utilização terapêutica
EP2125722A2 (en) * 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
PL2037967T3 (pl) 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego
JP5270542B2 (ja) * 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP5220013B2 (ja) 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
CN103172572A (zh) * 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
US8278310B2 (en) * 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
EP2396295A1 (en) 2009-02-12 2011-12-21 Merck Serono S.A. Phenoxy acetic acid derivatives
TW201118067A (en) * 2009-07-06 2011-06-01 Astrazeneca Ab Pharmaceutical process and intermediates
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
MA34094B1 (fr) 2010-03-22 2013-03-05 Actelion Pharmaceuticals Ltd Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
AU2013235439B2 (en) 2012-03-21 2017-11-23 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
MX2015012456A (es) 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
AU2014268477A1 (en) * 2013-05-24 2015-11-12 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
US20200078351A1 (en) 2015-07-30 2020-03-12 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
CA2156420A1 (en) 1993-02-24 1994-09-01 Theresa M. Williams Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
BR0307406A (pt) 2002-02-01 2004-12-28 Hoffmann La Roche Indóis substituìdos como agonistas alfa-1
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
EP2125722A2 (en) * 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
BRPI0712139A2 (pt) 2006-06-08 2012-01-10 Neurokey As uso de agonistas receptores de canabinóide como fármacos indutores de hipotermia para o tratamento da isquemia
KR20090023645A (ko) 2006-06-28 2009-03-05 사노피-아벤티스 신규한 ｃｘｃｒ2 억제제

Also Published As

Publication number Publication date
KR20110051297A (ko) 2011-05-17
US20080249110A1 (en) 2008-10-09
EP2025670B1 (en) 2011-03-16
AU2004242624A1 (en) 2004-12-09
AU2004242624B2 (en) 2008-03-13
CN1795174B (zh) 2011-09-28
PT1656346E (pt) 2009-05-20
HRP20110359T1 (hr) 2011-06-30
ES2382606T3 (es) 2012-06-11
IS8189A (is) 2005-12-20
IL171928A0 (en) 2006-04-10
US20090163518A1 (en) 2009-06-25
IL212371A0 (en) 2011-06-30
KR101067535B1 (ko) 2011-09-27
CY1109104T1 (el) 2014-07-02
ZA200509598B (en) 2006-12-27
CN1795174A (zh) 2006-06-28
HK1090635A1 (en) 2006-12-29
PL2025670T3 (pl) 2011-07-29
DE602004020072D1 (de) 2009-04-30
DE602004031894D1 (de) 2011-04-28
EP2281815B1 (en) 2012-04-04
IL212265A0 (en) 2011-06-30
JP2010155862A (ja) 2010-07-15
CA2526866A1 (en) 2004-12-09
US20110263614A1 (en) 2011-10-27
SE0301569D0 (sv) 2003-05-27
JP4541361B2 (ja) 2010-09-08
EP2281815A1 (en) 2011-02-09
ATE502010T1 (de) 2011-04-15
CY1112853T1 (el) 2016-02-10
BRPI0410711A (pt) 2006-06-13
NZ543722A (en) 2007-05-31
ES2322650T3 (es) 2009-06-24
EP1656346A1 (en) 2006-05-17
JP2007501269A (ja) 2007-01-25
ATE552243T1 (de) 2012-04-15
ATE425965T1 (de) 2009-04-15
RU2361860C2 (ru) 2009-07-20
IS2722B (is) 2011-03-15
EP1656346B1 (en) 2009-03-18
KR20110050754A (ko) 2011-05-16
NO20056130L (no) 2006-02-27
TW201024261A (en) 2010-07-01
TW200510301A (en) 2005-03-16
MXPA05012680A (es) 2006-02-08
CY1111469T1 (el) 2015-08-05
DK2025670T3 (da) 2011-06-06
PT2281815E (pt) 2012-05-24
SI1656346T1 (sl) 2009-08-31
ES2361485T3 (es) 2011-06-17
IL171928A (en) 2011-06-30
SI2025670T1 (sl) 2011-06-30
RU2005137403A (ru) 2006-05-27
HRP20090281T1 (en) 2009-06-30
WO2004106302A1 (en) 2004-12-09
CA2526866C (en) 2012-10-16
HK1149563A1 (is) 2011-10-07
IL194872A0 (en) 2011-08-01
SE0302305D0 (sv) 2003-08-27
HK1126773A1 (is) 2009-09-11
KR101067586B1 (ko) 2011-09-27
BRPI0410711B1 (pt) 2018-09-25
US7687535B2 (en) 2010-03-30
KR20060015303A (ko) 2006-02-16
BRPI0410711B8 (pt) 2021-05-25
HRP20120390T1 (hr) 2012-06-30
DK2281815T3 (da) 2012-06-18
US20120178764A1 (en) 2012-07-12
EP2025670A1 (en) 2009-02-18
PT2025670E (pt) 2011-05-24
PL2281815T3 (pl) 2012-08-31
SI2281815T1 (sl) 2012-06-29
AR044552A1 (es) 2005-09-21
TWI328004B (en) 2010-08-01
IS8920A (is) 2010-08-09
CN102391171A (zh) 2012-03-28
CO5630030A2 (es) 2006-04-28
MY144483A (en) 2011-09-30
PL1656346T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DK1556342T3 (da) Phenethanolaminderivat til behandling af respiratoriske sygdomme
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DE502004011765D1 (de) Implantat zur Spreizung der Nasenflügel
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
DK1699747T3 (da) Fremgangsmåde til fremstilling af 2,3-cis-substitueret 2-arylpropenaler
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne